Hot off the racks: The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare

Social Author Image
https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg
Tweet Author
RHEUMarampa
Social Author Name
sheila
Tweet Content
Hot off the racks: The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare rates vs PbO by depleting CD19-targeted B cells Game changer? Year in review. @RheumNow #ACR24 @rheumarhyme @marklagacmd @idatan @ljdado https://t.co/CZvdrymIyr
Links
https://x.com/RHEUMarampa/status/1857776021438595250/photo/1
https://x.com/RHEUMarampa/status/1857776021438595250/photo/1
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×